Product Description
COVID-19 Diagnostics: Global Market Forecasts by Technology, Product, Channel and Country - Assay Volumes & Market Size Outlook to 2026 (Includes 2021 Market Share)
April 2022 edition
The pandemic may be ending but Covid-19 is here to stay.
Who won the biggest share of the Covid Diagnostics market? How many tests were performed last year? 2021 broke all the records as Covid-19 testing reached all time highs in the final months of the year. Find out about this and the outlook for the years ahead. This is still a dynamic market as multiple competitors are vying for the very lucrative future for respiratory diagnostics.
The COVID-19 diagnostics market will remain strong for those who are prepared to pivot and jockey.
Our latest outlook discusses the opportunities and challenges facing the diagnostics organizations; breaking out test volume, market size and segment growth rates to 2026 by the following:
- Technology
- PCR, Multiplex PCR, Sequencing, Antibody, Antigen
- Product
- Instruments, Reagents and Kits, Extraction, Collection
- Channel
- Public, Hospital, Clinic, Workplace, DTC / OTC, Wastewater
- Country
- USA, Canada, Germany, France, UK, RoEUR, Japan, China, S. Korea, RoAP, Brazil, Mexico, RoLA, ME&A, Global
Additional data breakouts and custom data requests are available free of charge with the corporate license.
Learn all about this changing market and get on top of the situation quickly with our Market Guides and Situation Analysis. Make confident projections using the latest data.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready by phone or email to help you use it.
If a country forecast is not already listed, purchasers can request individual country market size information, or other customization, without additional charge with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
